Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.84
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-1.20 Insider Own3.24% Shs Outstand45.12M Perf Week-7.07%
Market Cap83.02M Forward P/E- EPS next Y-1.22 Insider Trans0.00% Shs Float43.66M Perf Month-22.03%
Income-51.89M PEG- EPS next Q-0.29 Inst Own35.30% Short Float9.43% Perf Quarter-40.65%
Sales3.82M P/S21.73 EPS this Y20.36% Inst Trans-7.27% Short Ratio15.01 Perf Half Y-22.03%
Book/sh0.95 P/B1.95 EPS next Y-2.81% ROA-71.48% Short Interest4.12M Perf Year-41.03%
Cash/sh1.21 P/C1.52 EPS next 5Y- ROE-111.08% 52W Range1.70 - 5.12 Perf YTD-30.30%
Dividend Est.- P/FCF- EPS past 5Y7.19% ROI-100.41% 52W High-64.06% Beta2.01
Dividend TTM- Quick Ratio3.34 Sales past 5Y118.97% Gross Margin17.15% 52W Low8.24% ATR (14)0.16
Dividend Ex-Date- Current Ratio3.34 EPS Y/Y TTM13.22% Oper. Margin-1392.60% RSI (14)40.81 Volatility7.12% 7.93%
Employees51 Debt/Eq0.38 Sales Y/Y TTM-59.13% Profit Margin-1358.33% Recom1.00 Target Price8.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q23.32% Payout- Rel Volume0.00 Prev Close1.84
Sales Surprise60.61% EPS Surprise26.15% Sales Q/Q2988.24% EarningsNov 09 AMC Avg Volume274.29K Price1.84
SMA20-5.99% SMA50-18.42% SMA200-33.08% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-13-24Initiated Jefferies Buy $6
Jun-26-23Resumed Oppenheimer Outperform $10
Nov-21-22Initiated Piper Sandler Overweight $7
Jan-13-22Initiated H.C. Wainwright Buy $20
Jan-03-22Initiated Craig Hallum Buy $28
Nov-24-20Initiated Berenberg Buy $30
Apr-09-20Initiated Stifel Buy $21
Jan-28-20Initiated BTIG Research Buy $26
Jan-22-20Initiated JMP Securities Mkt Outperform $22
Feb-29-24 10:00AM
Feb-06-24 08:00AM
Dec-14-23 07:04AM
Nov-22-23 08:00AM
Nov-12-23 12:55PM
04:05PM Loading…
Nov-09-23 04:05PM
Nov-07-23 08:00AM
Nov-03-23 12:00PM
Nov-02-23 08:00AM
Sep-28-23 05:39AM
Sep-27-23 09:05AM
Sep-26-23 08:00AM
Aug-10-23 10:37AM
10:19AM
08:28AM
04:10PM Loading…
Aug-09-23 04:10PM
Aug-02-23 08:00AM
Jun-22-23 06:40AM
Jun-14-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-26-23 06:19AM
May-25-23 05:00PM
May-15-23 08:00AM
May-09-23 05:55PM
04:35PM
May-08-23 08:00AM
May-05-23 02:24PM
May-04-23 01:56PM
Apr-25-23 08:00AM
08:00AM Loading…
Apr-12-23 08:00AM
Mar-28-23 10:45AM
Mar-24-23 07:28AM
Mar-22-23 07:37AM
Mar-21-23 04:10PM
Mar-15-23 08:00AM
Mar-01-23 08:00AM
Feb-22-23 08:00AM
Feb-16-23 10:30AM
08:00AM
Feb-14-23 05:49AM
Feb-01-23 08:00AM
Jan-23-23 08:00AM
Nov-22-22 08:00AM
Nov-17-22 09:00AM
Nov-16-22 05:33AM
Nov-14-22 04:01PM
08:20AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Oct-17-22 12:18PM
Oct-05-22 08:00AM
Oct-04-22 08:00AM
Sep-07-22 08:00AM
Aug-26-22 06:21AM
Aug-23-22 04:30PM
09:55AM
Aug-22-22 08:00AM
Aug-04-22 04:30PM
06:35AM
Jul-11-22 08:00AM
Jun-27-22 10:49AM
Jun-13-22 08:00AM
Jun-02-22 06:56AM
Jun-01-22 08:00AM
May-26-22 05:00PM
May-11-22 08:00AM
May-10-22 04:30PM
11:23AM
May-06-22 08:25AM
May-05-22 09:45AM
May-04-22 06:25PM
Apr-05-22 09:09PM
Apr-04-22 09:06AM
Mar-23-22 09:25AM
Mar-19-22 08:19AM
Mar-10-22 08:00AM
Mar-09-22 05:15PM
Mar-02-22 08:00AM
Feb-24-22 05:40PM
Feb-23-22 09:00PM
Feb-15-22 08:22AM
08:00AM
Feb-13-22 06:28PM
08:46AM
Jan-27-22 05:24AM
Jan-26-22 04:01PM
Jan-20-22 08:00AM
Jan-05-22 08:00AM
Dec-30-21 05:49AM
Dec-15-21 08:00AM
Dec-06-21 08:00AM
Nov-22-21 08:00AM
Nov-15-21 05:42AM
Nov-12-21 08:00AM
Nov-10-21 08:00AM
Nov-09-21 03:00PM
Oct-21-21 12:00PM
Oct-04-21 08:00AM
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Suri AnishPRESIDENT AND CSOAug 25 '23Buy2.764,00011,040135,638Aug 29 04:08 PM
PASSERI DANIEL RCHIEF EXECUTIVE OFFICERAug 14 '23Buy2.863,0008,580134,578Aug 16 04:07 PM
Last Close
Mar 27 04:00PM ET
6.59
Dollar change
0.00
Percentage change
0.00
%
TFFP Tff Pharmaceuticals Inc daily Stock Chart
Index- P/E- EPS (ttm)-15.76 Insider Own0.00% Shs Outstand2.37M Perf Week-17.11%
Market Cap15.62M Forward P/E- EPS next Y-6.48 Insider Trans- Shs Float2.37M Perf Month25.29%
Income-23.85M PEG- EPS next Q-1.92 Inst Own14.92% Short Float1.96% Perf Quarter-5.99%
Sales0.00M P/S- EPS this Y45.94% Inst Trans12.54% Short Ratio1.81 Perf Half Y-21.62%
Book/sh5.79 P/B1.14 EPS next Y-2.37% ROA-135.87% Short Interest0.05M Perf Year-61.85%
Cash/sh4.11 P/C1.61 EPS next 5Y- ROE-150.43% 52W Range4.55 - 21.25 Perf YTD-6.13%
Dividend Est.- P/FCF- EPS past 5Y-155.78% ROI-173.57% 52W High-68.98% Beta1.30
Dividend TTM- Quick Ratio9.54 Sales past 5Y0.00% Gross Margin- 52W Low44.84% ATR (14)1.09
Dividend Ex-Date- Current Ratio9.54 EPS Y/Y TTM53.55% Oper. Margin0.00% RSI (14)44.04 Volatility16.29% 16.30%
Employees15 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price25.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q67.48% Payout- Rel Volume0.00 Prev Close6.59
Sales Surprise369.60% EPS Surprise21.74% Sales Q/Q- EarningsNov 14 AMC Avg Volume25.60K Price6.59
SMA20-14.72% SMA50-0.80% SMA200-19.35% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
May-19-22Resumed H.C. Wainwright Buy $22
Feb-08-21Initiated H.C. Wainwright Buy $31
Dec-07-20Initiated B. Riley Securities Buy $36
Aug-17-20Reiterated Maxim Group Buy $12 → $18
Jul-08-20Initiated Maxim Group Buy $12
Mar-27-24 04:01PM
Mar-25-24 09:01AM
Mar-22-24 03:11PM
Mar-20-24 12:00PM
09:03AM
04:47PM Loading…
Mar-14-24 04:47PM
Jan-24-24 08:00AM
Jan-09-24 08:00AM
Dec-20-23 10:52AM
10:52AM
Dec-19-23 06:00AM
Dec-18-23 04:01PM
Dec-15-23 07:00AM
Dec-13-23 08:00AM
Nov-30-23 08:00AM
08:00AM Loading…
08:00AM
Nov-27-23 07:00AM
Nov-16-23 08:37AM
Nov-14-23 04:05PM
Nov-08-23 04:05PM
Nov-07-23 04:05PM
Oct-02-23 05:00PM
Sep-28-23 04:29PM
Aug-23-23 07:00AM
Aug-17-23 04:01PM
06:36AM
Aug-16-23 04:25AM
Aug-15-23 06:05AM
06:00AM
Aug-14-23 04:01PM
08:30AM Loading…
Aug-09-23 08:30AM
Aug-08-23 05:50PM
Jul-31-23 07:00AM
Jun-26-23 07:00AM
May-23-23 04:05PM
May-11-23 04:05PM
May-09-23 07:15AM
May-04-23 08:00AM
May-01-23 07:00AM
Apr-08-23 08:58AM
Mar-07-23 04:15PM
Mar-06-23 04:05PM
Feb-23-23 01:01PM
Feb-08-23 04:05PM
Jan-09-23 08:00AM
Dec-05-22 06:30AM
Nov-29-22 04:01PM
Nov-21-22 01:40PM
Nov-18-22 08:00AM
Nov-17-22 04:01PM
05:34AM
Nov-14-22 04:01PM
Nov-07-22 04:05PM
Nov-03-22 08:00AM
Nov-02-22 12:47PM
Nov-01-22 04:07PM
04:05PM
Oct-18-22 10:23AM
Oct-11-22 08:00AM
Sep-26-22 08:00AM
Sep-22-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-12-22 11:30AM
Aug-11-22 04:05PM
Aug-02-22 04:05PM
Jul-14-22 08:00AM
Jun-24-22 03:44PM
Jun-09-22 08:00AM
Jun-01-22 08:00AM
May-31-22 09:55AM
May-20-22 09:32AM
May-11-22 05:15PM
04:01PM
May-10-22 03:34PM
May-02-22 08:00AM
Apr-29-22 07:30AM
Apr-28-22 08:04AM
Apr-19-22 08:00AM
Apr-05-22 09:09PM
Mar-25-22 12:00AM
Mar-24-22 05:45PM
04:26PM
Mar-17-22 11:07AM
08:00AM
Mar-11-22 07:05AM
Mar-09-22 04:05PM
Mar-07-22 10:16AM
Mar-01-22 08:00AM
Feb-24-22 02:29PM
09:27AM
Jan-27-22 08:00AM
Jan-12-22 09:34AM
Dec-21-21 08:00AM
Dec-06-21 08:00AM
Nov-16-21 01:00AM
Nov-15-21 05:25PM
04:01PM
Nov-08-21 08:03AM
08:00AM
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARLSON CAPITAL L P10% OwnerAug 16 '23Sale0.391,0003925,064,000Aug 17 05:29 PM
Weisman Harlan FPresident and CEOAug 15 '23Buy0.25600,000150,000814,615Aug 15 08:00 AM
Mikhak ZamanehChief Medical OfficerAug 15 '23Buy0.25120,00030,000135,000Aug 15 08:00 AM
MILLS ROBERT SDirectorAug 15 '23Buy0.2540,00010,00055,980Aug 15 08:00 AM
COLEMAN KIRK ALLENChief Financial OfficerAug 15 '23Buy0.2520,0005,00035,675Aug 15 08:00 AM
Roberts BrandiDirectorAug 15 '23Buy0.2520,0005,00020,000Aug 15 08:00 AM
ROCAMBOLI STEPHENDirectorAug 15 '23Buy0.2520,0005,00036,000Aug 15 08:00 AM
CARLSON CAPITAL L P10% OwnerAug 15 '23Sale0.44215,00094,0415,065,000Aug 17 05:29 PM